LY 3962673
Alternative Names: LY-3962673Latest Information Update: 03 Oct 2024
At a glance
- Originator Loxo Oncology
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 15 Sep 2024 Eli Lilly and Company plans a phase I trial for Solid tumours (Monotherapy, Combination therapy, Late stage disease, Metastatic disease, Unresectable/Inoperable) (PO) in September 2024 (NCT06586515)
- 12 Sep 2024 Phase-I clinical trials in Solid tumours (Metastatic disease, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT06586515)
- 12 Sep 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT06586515)